2-methoxyethyl prop-2-enoate Cas:3121-61-7

We are 2-methoxyethyl prop-2-enoate CAS:3121-61-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


2-methoxyethyl prop-2-enoate

Synonyms:
Methyl cellosolve acrylate
Ethylene Glycol Monomethyl Ether Acrylate
2-Methoxyethoxy acrylate
2-METHOXYETHYL ACRYLATE
2-Propenoic acid,2-methoxyethyl ester
1-Acryloyloxy-2-methoxy-aethan
Ethylene Glycol Methyl Ether Acrylate
2-Propenoic acid, 2-methoxyethyl ester
Sipomer MCA
acrylic acid 2-methoxy-ethyl ester
Methoxyethyl acrylate
n-methoxyethyl acrylate
Ethylene glycol methyl ether acrylate,stabilized
Acrylic Acid 2-Methoxyethyl Ester
2-Methoxyethanol,acrylate
 
molecular formula: C6H10O3
Molecular weight: 130.14200
 
Physical Properties:
Appearance and Properties: Transparent colorless liquid with a strong musty odor
Density: 1.012 g/mL at 25 °C(lit.)
Boiling point: 56 °C12 mm Hg(lit.)
Melting point: -30°C
Flash point: 140 °F
Refractive index: n20/D 1.427(lit.)
 
Specification:
 

Items of Analysis Standard of Analysis Test Results
Appearance Colorless transparent liquid Conform
Purity ≥99% 99.4%
Color ≤20 3
Acidity ≤0.03% 0.003%
Moisture ≤0.1% 0.016%
 Inhibitor (MEHQ) 100±10 ppm 107 ppm
Conclusion Conforms to Factory Standard
 

Application:
Pharmaceutical intermediates
 
Package and Storage:
Keep container tightly closed. Store in a cool, dark, well-ventilated place.



Market News:These have since been joined by many other types of enzyme, including transaminases, oxidases, nitrilases, aldolases, and ammonia lyases, all of which perform distinct functions. {(NH3)5Co(III)(imidazole)}(3+) manufacturer.EMA’s human medicines committee (CHMP) has endorsed findings of a review which concluded that there is no evidence Zynteglo causes a blood cancer known as acute myeloid leukaemia (AML). 4-hydroxy-5-oxo-3,4-dihydro-pyrazine-2-carboxylic acid supplier.SARS-CoV-2 has evolved mutations that severely compromise the neutralizing activities of multiple IgG monoclonal antibodies, including those under clinical trials and authorized for emergency use.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. 6-Amino-hexylamid des sauren Adipinsaeureglycerids producer.

Related Products
Product Name
4-Bromo-2-fluoro-1-(trifluoromethoxy)benzene View Details
Triisobutyl phosphate View Details
F-Ara-A View Details
4-Bromo-2-chlorobenzonitrile manufacturer ethyl(trimethyl)silane manufacturer 2-(Difluoromethoxy)aniline manufacturer α-(CHLOROMETHYL)-2,4-DICHLOROBENZYL ALCOHOL manufacturer 4-N-(3-chloro-4-fluorophenyl)-7-(3-morpholin-4-ylpropoxy)quinazoline-4,6-diamine manufacturer